Eisai Company Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.

It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer.

The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.

It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate; and a clinical trial collaboration and supply agreement with Medivir for the evaluation of fostrox, a liver-targeted treatment.

Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.

Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Eisai Co., Ltd.

Country	Japan
Founded	1941
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	11,067
CEO	Haruo Naito

Contact Details

Address: 4-6-10, Koishikawa Tokyo, 112-8088 Japan
Phone	81 3 3817 3700
Website	eisai.co.jp

Stock Details

Ticker Symbol	4523
Exchange	Tokyo Stock Exchange
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3160400002
SIC Code	2834

Key Executives

Name	Position
Haruo Naito	Chief Executive Officer
Mitsuru Shomon	Chief Financial Officer
Keisuke Naito	Chief Operating Officer
Masatomi Akana	Head of Investor Relations